BLA 761334 · Incyte Corp
Zynyz
Retifanlimab-Dlwr · Intravenous · Programmed Death Receptor-1 Blocking Antibody
NovelAccelerated approvalPriority reviewOrphanCDER novel approval, Mar 22, 2023: To treat metastatic or recurrent locally advanced Merkel cell carcinoma
Last checked: Nov 20, 2026Latest source record: May 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Mar 22, 2023
Approved uses
5
Original approval plus efficacy supplements
Registered trials
62
5 Phase 3, 17 recruiting
FAERS reports
72
43 serious, 9 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 18, 2026.
ZYNYZ is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Squamous Cell Carcinoma of the Anal Canal (SCAC) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). ( 1.1 ) as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. ( 1.1 ) Merkel Cell Carcinoma (MCC) for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). ( 1.2 ) 1.1 Squamous Cell Carcinoma of the Anal Canal ZYNYZ, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). ZYNYZ, as a single agent, is indicated for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum‑based chemotherapy. 1.2 Merkel Cell Carcinoma ZYNYZ is indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).
Mechanism: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Retifanlimab-dlwr binds to the PD-1 receptor, blocks interaction with its ligands PD-L1 and PD‑L2, and potentiates T-cell activity.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 18, 2026 Supplement 9 · Efficacy OrphanLabelLetter
- Mar 30, 2026 Supplement 8 · Efficacy OrphanLabelLetterMedication Guide
- Dec 17, 2025 Supplement 5 · Efficacy OrphanLetterLabel
- May 15, 2025 Supplement 4 · Efficacy · priority review OrphanLabelLetter
- Mar 22, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelMedication GuideLetter
1 products under this application
- ZYNYZ · RETIFANLIMAB-DLWR 500MG/20ML(25MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Retifanlimab" as an intervention, any sponsor and status, largest first.
Incyte CorporationIncyte (INCY)
NCT06179160 · 710 participants (planned) · Start Jan 4, 2024 · Primary completion Jan 1, 2027
Drug: INCB161734; Cetuximab and 6 more · For: Solid Tumors
Sites: Phoenix, Arizona; Palo Alto, California; Santa Monica, California · 34 sites in all
- Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerPivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT04205812 · 583 participants · Start Sep 11, 2020 · Primary completion Dec 15, 2023
Drug: Retifanlimab; Placebo and 5 more · For: Metastatic Squamous Non-Small Cell Lung Cancer; Metastatic Nonsquamous Non-Small Cell Lung Cancer
Sites: Anaheim, California; Whittier, California; Reading, Pennsylvania · 140 sites in all
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.Pivotal-lookingRecruiting
BriaCell Therapeutics CorporationIndustry
NCT06072612 · 404 participants (planned) · Start Dec 5, 2023 · Primary completion Dec 2027
Drug: SV-BR-1-GM; Cyclophosphamide and 3 more · For: Breast Cancer; Metastatic Breast Cancer; Breast Neoplasm and 2 more
Sites: Phoenix, Arizona; Tucson, Arizona; Anaheim, California · 79 sites in all
Incyte CorporationIncyte (INCY)
NCT03059823 · 325 participants · Start Nov 15, 2016 · Primary completion May 22, 2024
Drug: retifanlimab · For: Locally Advanced Solid Tumors; Metastatic Solid Tumors
Sites: Scottsdale, Arizona; Grand Rapids, Michigan; New Brunswick, New Jersey · 80 sites in all
- Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).Pivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT04472429 · 308 participants · Start Nov 9, 2020 · Primary completion Apr 15, 2024
Drug: carboplatin; paclitaxel and 1 more · For: Squamous Cell Carcinoma of the Anal Canal
Sites: Tucson, Arizona; Duarte, California; Sacramento, California · 84 sites in all
Incyte CorporationIncyte (INCY)
NCT04463771 · 206 participants · Start Jan 26, 2021 · Primary completion May 29, 2026
Drug: retifanlimab; epacadostat and 3 more · For: Endometrial Cancer
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 65 sites in all
Incyte CorporationIncyte (INCY)
NCT02393248 · 201 participants · Start Feb 27, 2015 · Primary completion Dec 17, 2021
Drug: Pemigatinib; Gemcitabine and 5 more · For: Lung Cancer; Solid Tumor; Gastric Cancer and 8 more
Sites: Birmingham, Alabama; West Hollywood, California; New Haven, Connecticut · 20 sites in all
- Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckPivotal-lookingCompleted
Incyte Biosciences International SàrlIncyte (INCY)
NCT05287113 · 176 participants · Start Nov 14, 2022 · Primary completion Mar 14, 2025
Drug: Retifanlimab; INCAGN02385 and 2 more · For: Head and Neck Cancer
Sites: Scottsdale, Arizona; Duarte, California; Irvine, California · 91 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use25
- disease progression11
- anal squamous cell carcinoma6
- anal cancer5
- death4
- malignant neoplasm progression4
- nausea4
- anaemia3
- condition aggravated3
- decreased appetite3
- malaise3
- neuropathy peripheral3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 24 |
| 2026 | 44 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Zynyz (Retifanlimab-Dlwr) · HCPCS J9345
2024 spending
$1.0M
Beneficiaries
24
75 claims
Per beneficiary
$43,406
2024 ASP limit $29.47 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $229,465 |
| 2024 | $1,041,751 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.
Rao S, Samalin-Scalzi E, Evesque L, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).
Rao S, Anandappa G, Capdevila J, et al. · ESMO Open 2022 · Clinical Trial, Phase II, Multicenter Study
- Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study.
Lu S, Vynnychenko O, Kulyaba Y, et al. · Lancet Respir Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201).
Grignani G, Rutkowski P, Lebbé C, et al. · J Immunother Cancer 2025 · Clinical Trial, Phase II, Multicenter Study
- Survival outcomes in POD1UM-303/InterAACT-2: a phase III study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer.
Rao S, Samalin-Scalzi E, Evesque L, et al. · Ann Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).
Di Giacomo AM, Schenker M, Medioni J, et al. · ESMO Open 2024 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Incyte
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.